Alvaiz is a drug owned by Teva Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 05, 2038. Details of Alvaiz's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US11072586 | Solid state forms of eltrombopag choline |
Nov, 2038
(13 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but Alvaiz is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Alvaiz's family patents as well as insights into ongoing legal events on those patents.
Alvaiz's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Alvaiz's generic launch date based on the expiry of its last outstanding patent is estimated to be Nov 05, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Alvaiz Generics:
There are no approved generic versions for Alvaiz as of now.
About Alvaiz
Alvaiz is a drug owned by Teva Pharmaceuticals Inc. Alvaiz uses Eltrombopag Choline as an active ingredient. Alvaiz was launched by Teva Pharms Inc in 2023.
Approval Date:
Alvaiz was approved by FDA for market use on 29 November, 2023.
Active Ingredient:
Alvaiz uses Eltrombopag Choline as the active ingredient. Check out other Drugs and Companies using Eltrombopag Choline ingredient
Dosage:
Alvaiz is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 9MG BASE | TABLET | Prescription | ORAL |
| EQ 54MG BASE | TABLET | Prescription | ORAL |
| EQ 36MG BASE | TABLET | Prescription | ORAL |
| EQ 18MG BASE | TABLET | Prescription | ORAL |